Sartorius Stedim Biotech S.A.

ENXTPA:DIM Stock Report

Market Cap: €16.7b

Sartorius Stedim Biotech Valuation

Is DIM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DIM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DIM (€167.3) is trading above our estimate of fair value (€120.08)

Significantly Below Fair Value: DIM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DIM?

Key metric: As DIM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DIM. This is calculated by dividing DIM's market cap by their current earnings.
What is DIM's PE Ratio?
PE Ratio101.4x
Earnings€160.60m
Market Cap€16.66b

Price to Earnings Ratio vs Peers

How does DIM's PE Ratio compare to its peers?

The above table shows the PE ratio for DIM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.2x
ERF Eurofins Scientific
26.5x18.3%€8.6b
PCA PCAS
12.5xn/a€109.9m
IPN Ipsen
13.2x7.0%€8.8b
ALECR Eurofins-Cerep
12.7xn/a€97.3m
DIM Sartorius Stedim Biotech
101.4x31.9%€16.3b

Price-To-Earnings vs Peers: DIM is expensive based on its Price-To-Earnings Ratio (101.4x) compared to the peer average (16.2x).

Price to Earnings Ratio vs Industry

How does DIM's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
DIM 101.4xIndustry Avg. 37.1xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DIM is expensive based on its Price-To-Earnings Ratio (101.4x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is DIM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DIM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio101.4x
Fair PE Ratio34x

Price-To-Earnings vs Fair Ratio: DIM is expensive based on its Price-To-Earnings Ratio (101.4x) compared to the estimated Fair Price-To-Earnings Ratio (33.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DIM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€167.30
€220.67
+31.9%
18.2%€310.00€134.00n/a15
Nov ’25€192.00
€220.67
+14.9%
18.2%€310.00€134.00n/a15
Oct ’25€184.45
€213.93
+16.0%
20.5%€310.00€134.00n/a14
Sep ’25€184.00
€207.31
+12.7%
20.8%€310.00€134.00n/a13
Aug ’25€184.15
€207.31
+12.6%
20.8%€310.00€134.00n/a13
Jul ’25€146.70
€247.17
+68.5%
17.8%€360.00€180.00n/a12
Jun ’25€182.65
€248.83
+36.2%
16.8%€360.00€200.00n/a12
May ’25€203.00
€251.33
+23.8%
16.9%€360.00€200.00n/a12
Apr ’25€264.30
€261.23
-1.2%
15.8%€360.00€205.00n/a12
Mar ’25€253.10
€254.69
+0.6%
17.1%€360.00€190.00n/a14
Feb ’25€248.20
€253.12
+2.0%
18.3%€360.00€190.00n/a14
Jan ’25€239.50
€230.56
-3.7%
14.8%€310.00€175.00n/a12
Dec ’24€202.00
€224.31
+11.0%
14.5%€310.00€175.00n/a12
Nov ’24€180.15
€252.42
+40.1%
22.5%€390.00€175.00€192.0012
Oct ’24€226.00
€308.73
+36.6%
12.3%€390.00€265.00€184.4511
Sep ’24€263.30
€306.45
+16.4%
12.5%€390.00€270.00€184.0011
Aug ’24€270.40
€303.73
+12.3%
13.5%€390.00€250.00€184.1511
Jul ’24€228.70
€334.18
+46.1%
22.7%€530.00€250.00€146.7011
Jun ’24€253.30
€363.82
+43.6%
18.5%€530.00€285.00€182.6511
May ’24€242.50
€376.70
+55.3%
17.6%€530.00€300.00€203.0010
Apr ’24€282.00
€395.27
+40.2%
10.5%€455.00€306.00€264.3011
Mar ’24€306.20
€395.91
+29.3%
10.7%€455.00€306.00€253.1011
Feb ’24€324.40
€394.73
+21.7%
10.3%€455.00€306.00€248.2011
Jan ’24€302.50
€411.20
+35.9%
12.3%€470.00€290.00€239.5010
Dec ’23€342.90
€411.20
+19.9%
12.3%€470.00€290.00€202.0010
Nov ’23€314.00
€418.45
+33.3%
13.0%€497.00€290.00€180.1511

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Sanofi

€114.5b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€91.47

7D

-4.4%

1Y

7.1%

Eurofins Scientific

€8.6b

Provides various analytical testing and laboratory services worldwide.

ERF

€45.57

7D

-1.3%

1Y

-11.3%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

7D

1.2%

1Y

-58.0%